Key Highlights

  • Net sales for BVS in the third quarter of 2026 totaled $142.4 million, versus $138.7 million a year before.
  • Profit of $6.9 million compares with $4.0 million, while adjusted diluted EPS climbed 13% to $0.17.
  • The adjusted EBITDA figure of $28 million equaled a 20% margin, widening 70 basis points on the prior-year quarter.
  • Net Debt dipped under $200 million once $19 million in term debt had been retired, with 2026 retirements totaling $65 million.
  • The Revenue forecast for 2026 was reduced to between $590 million and $595 million, while the per-share outlook, between $0.75 and $0.79 on an adjusted basis, was kept.

Pain Franchise Growth Partly Cancels Weakness in Bone Graft Products

The third quarter, which ended Sep 26, 2026, was reported on Nov 2, 2026 by Bioventus (NASDAQ:BVS). Net sales rose roughly 3%, arriving at $142.4 million from $138.7 million, and profit reached $6.9 million, up from $4.0 million. On a GAAP diluted basis, Class A shareholders earned $0.08 per share, against $0.05.

Based in Durham, North Carolina, the medical device maker sells pain relief and musculoskeletal recovery products, including HA injections, bone grafts and ultrasonic surgical instruments. Pain therapy sales grew 6%, to $71 million. Surgical solutions rose by 1%, arriving at $51 million, with ultrasonics growing in double digits.

Bone graft substitutes contracted 6%; management blamed modest softness in spine cases, slow onboarding of distributors and rivalry in synthetic grafts. Restorative therapies declined 3% to $21 million, reflecting open sales roles in the EXOGEN team, which reduced volume. Overseas sales increased 16%, totaling $18 million; excluding currency effects the rise was 18%.

Lower Borrowing Costs Help Hold the Adjusted EBITDA Margin at 20%

Adjusted EBITDA hit $28 million, close to $2 million above last year, producing a 20% margin. Adjusted EPS was $0.17, while the prior-year figure was $0.15; the year-to-date adjusted EPS total rose 18%.

Operating income fell to $9.7 million from $11.3 million as SG&A expanded, reaching $82.9 million versus $78.7 million a year earlier. Net interest expense decreased to $3.8 million, down from $6.2 million. Nine-month Net Income was $47.0 million, including a $21.0 million tax benefit.

Leverage Slips Under $200 Million While the Board Weighs Strategic Options

Operating cash generation reached $21 million during the quarter. The Balance Sheet showed $31 million in cash against $230 million in debt outstanding, and the company projects net Leverage under 1.5x by year-end.

Management disclosed that the board is assessing strategic alternatives with advisers, a process triggered by an unsolicited Takeover offer and several expressions of interest. No further detail was offered.

In the business, platelet-rich plasma now produces more revenue from disposable kits than from equipment placements. Within peripheral nerve stimulation, trained physicians rose by over half from the previous quarter.

Bone Graft Softness Trims the Revenue Band as Fourth-Quarter Growth Stays Positive

The 2026 revenue forecast was reduced by roughly $12 million at the midpoint, mainly because of bone graft substitutes, to $590 million through $595 million. For the fourth quarter, the company still foresees a mid-single-digit percent increase in revenue, plus international expansion above 20%.

The per-share guidance on an adjusted basis, between $0.75 and $0.79, was retained, and adjusted operating cash of $84 million to $89 million stayed unchanged. The margin outlook for adjusted EBITDA has been raised above last year's figure. According to management, bone graft Demand in October outpaced internal projections, and the strategic review is still the chief unresolved matter.